Preparing healthcare companies for success
in the value-based economy

New Access Meter Report
NOW AVAILABLE

more info >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

Our Solutions

Value-Based Dealmaker

Design and orchestrate value-based deals

RxScorecardTM

Guide strategic and development decisions with customized, interactive value framework

Access Meter

Defining payer challenges for emerging drugs with a validated database

Hub ExcellenceTM

Maximize the impact of patient services programs via benchmarking and needs analysis

Reimbursement iQTM

Enhance impact of customer-facing representatives using 360˚analysis

Customer Gateway

Develop customized program to foster goodwill with customers

Communications
and Training

Address customer pain points with targeted materials; strengthen confidence and knowledge of reps via customized training

Advisory and
Market Research

Generate strategic recommendations — conduct qualitative and quantitative research

News and Events

The Rock Just Below the Water: Market Access Risk and Early-stage Biotechs Webinar

Panelists: Jeffrey Berkowitz, Real Endpoints
Roger Longman, Real Endpoints
Dennis Purcell, Aisling Capital

The pharmaceutical landscape is littered with the market-access failures of recent biotech launches – the reason investors now often “sell on the launch” -- innovative science and a biotechs’ vision of “unmet medical need” are often irrelevant or meaningless to payers. Even the earliest target product profile needs to reflect “unmet need” from the payer’s point of view – using an objective, broad and forward-looking understanding of competition -- and create a medical and economic roadmap for minimizing payer restrictions.

December 14, 2018
12:45 PM EST

event >

Jeff Berkowitz Takes Helm of Real Endpoints

by PharmaVoice

Real Endpoints, which provides development and implementation of proprietary tools, has named Jeff Berkowitz as CEO and member of the board of directors. Most recently, Mr. Berkowitz served as an executive VP at UnitedHealth Group, CEO of it Optum International business, and as a strategic leader of OptumRx, its PBM, Mr. Berkowitz is a PharmaVOICE Red Jacket - 2014.

October 16, 2018

PharmaVoice

Read full article >

AMCP Nexus

Attendee: Real Endpoints team

The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.

October 22, 2018 -
October 25, 2018

Orlando, FL

event >

Must Sky-High Prices ‘Come on Down’ Before the Price Is Right?

by Richard Mark Kirkner

The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?

July 25, 2018

Managed Care

read full article >

Recent Insights

view archive >

November 18, 2018

What rebates? Express Scripts touts a new plan to appease critics of the opaque drug-pricing system

Amid national angst over prescription drug pricing, Express Scripts is touting a new scheme it says will lessen the behind-the-scenes role that rebates play in rising costs. In effect, Express Scripts would create a two-tier system for its customers which could choose between a formulary with a high list price and high rebate, or the newer plan that will offer a lower list price and lower or no rebate.

read full insight article >

November 5, 2018

Backing into Value with Part B

Jeff Berkowitz, CEO, Real Endpoints' is quoted, "It becomes a global index that reflects the value as seen by number of different entities against all of the other choices they need to make from a health delivery perspective."

read full insight article >
Just a quick note of appreciation for your responsiveness throughout the Market Access training process.  Your follow-up on a range of issues was always immediate and the resolution was definitive.  That type of effort and support doesn’t go unnoticed by me.

National Business Director

Top 5 Pharma

We have never seen a diagnostic like this before – it gets right to the heart of the problem.

Senior Director

Specialty Access Solutions, Top 5 Pharma

The insights you provided via Hub Excellence were the most insightful and actionable market research I have ever received.

Director of Operations

Reimbursement and Patient Support Services, Top 20 Pharma

RxScorecard provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology.

Chronis H. Manolis, RPh

Vice President, Pharmacy UPMC Health Plan

We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.

Jack Bailey

President , GlaxoSmithKline U.S.